BOSTON and SOUTH SAN FRANCISCO, Calif. — October 22, 2025 — Leads & Copy — Frontier Medicines Corporation will present preclinical data from three of its pipeline programs at the 37th AACR-NCI-EORTC International Conference on Molecular Targets in Boston, MA, from October 22 to 26.
FMC-376 demonstrated anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream pathways compared to sotorasib. FMC-220 potently and selectively restored p53 tumor suppressor function and delivered tumor regressions in p53 Y220C mutant preclinical models. FMC-242, a covalent PI3Kα/RAS breaker, shows anti-tumor activity and enhanced efficacy in combination with other therapies.
According to Kevin Webster, Ph.D., chief scientific officer of Frontier Medicines, data presented at the Triple Meeting is a testament to the company’s ability to execute across programs and to the power of the Frontier™ Platform. Webster noted that FMC-376 blocks both the ON and OFF states of the G12C mutant KRAS protein, leading to a complete and durable blockade of downstream signaling, and in preclinical models, this translated to robust anti-tumor activity as a single agent, and synergistic activity when combined with cetuximab. FMC-220 also showed significant promise, demonstrating tumor regressions in preclinical models as a single agent, and efficacy when combined with other therapeutics, including MDM2 inhibitors or DNA-damaging agents. Finally, FMC-242 demonstrated deep inhibition of the PI3Kα-RAS interaction and potent anti-tumor activity, including tumor regressions, in preclinical models, and enhanced efficacy when combined with KRAS or EGFR inhibitors.
Media Contact: pr@frontiermeds.com
Source: Frontier Medicines
